Data-driven precision medicine ecosystem - stakeholder needs and opportunities

    Research output: Book/ReportPublished reportResearch

    Abstract

    This report summarizes the results of the first phase of VTT's PreMed project. It provides an overview of the Finnish precision medicine landscape and business opportunities opened by secondary use of health related data as enabled by biobanks and other data sources. The observations are based on openly available information and interviews of key stakeholders. The report describes the Finnish infrastructure supporting secondary use and covers the existing entities (e.g. biobanks), entities currently in development (e.g. the Service Operator and Genome Center) and related national activities, most notably the FinnGen project. It is concluded that the Finnish infrastructure is well-developed and internationally competent, but there are worries among the stakeholders concerning the delays in setting up the components under development. Analysis of international developments reveals that a large number of efforts is on-going targeted at collecting genome data, supporting co-operation and improving access to data and processing tools. Although the international market potential is high, most Finnish SME's in the precision medicine domain still have difficulties in generating profitable business. The related reasons and bottlenecks are analysed and new business opportunities are analysed in the report. The potential of Artificial Intelligence is specifically addressed as a technology powered by the increased availability of health data for secondary use. The report provides an analysis of business opportunities in four areas covering new therapy development, health risk assessment and diagnostics, therapy selection and direct-to-consumer genomics. The analysis provides policies and strategies, which should be adopted to remove the main barriers. It is widely understood that successful business in data-driven precision medicine relies on networked stakeholders. In order to understand the mechanisms of the business ecosystem an initial ecosystem model has been constructed in the PreMed project. The model enables simulation of different alternative development paths for the precision medicine ecosystem. The report forms the basis for further work planned to be carried out in the PreMed project, which is scheduled to be completed by April 2020.
    LanguageEnglish
    PublisherVTT Technical Research Centre of Finland
    Number of pages74
    Publication statusPublished - 29 Aug 2018
    MoE publication typeNot Eligible

    Publication series

    NameResearch Report
    PublisherVTT
    No.VTT-R-03318-18

    Fingerprint

    medicine
    stakeholder
    ecosystem
    genome
    infrastructure
    artificial intelligence
    health risk
    need
    genomics
    risk assessment
    market
    project
    simulation
    analysis
    health
    therapy

    Keywords

    • precision medicine
    • personalized medicine
    • secondary use
    • artificial intelligence
    • genome technology
    • biobank
    • business ecosystem

    OKM Publication Types

    • D4 Report

    OKM Open Access Status

    • 1 Open Access

    Cite this

    @book{a9a445fa9893412e8ddf5b3a2adf36c3,
    title = "Data-driven precision medicine ecosystem - stakeholder needs and opportunities",
    abstract = "This report summarizes the results of the first phase of VTT's PreMed project. It provides an overview of the Finnish precision medicine landscape and business opportunities opened by secondary use of health related data as enabled by biobanks and other data sources. The observations are based on openly available information and interviews of key stakeholders. The report describes the Finnish infrastructure supporting secondary use and covers the existing entities (e.g. biobanks), entities currently in development (e.g. the Service Operator and Genome Center) and related national activities, most notably the FinnGen project. It is concluded that the Finnish infrastructure is well-developed and internationally competent, but there are worries among the stakeholders concerning the delays in setting up the components under development. Analysis of international developments reveals that a large number of efforts is on-going targeted at collecting genome data, supporting co-operation and improving access to data and processing tools. Although the international market potential is high, most Finnish SME's in the precision medicine domain still have difficulties in generating profitable business. The related reasons and bottlenecks are analysed and new business opportunities are analysed in the report. The potential of Artificial Intelligence is specifically addressed as a technology powered by the increased availability of health data for secondary use. The report provides an analysis of business opportunities in four areas covering new therapy development, health risk assessment and diagnostics, therapy selection and direct-to-consumer genomics. The analysis provides policies and strategies, which should be adopted to remove the main barriers. It is widely understood that successful business in data-driven precision medicine relies on networked stakeholders. In order to understand the mechanisms of the business ecosystem an initial ecosystem model has been constructed in the PreMed project. The model enables simulation of different alternative development paths for the precision medicine ecosystem. The report forms the basis for further work planned to be carried out in the PreMed project, which is scheduled to be completed by April 2020.",
    keywords = "precision medicine, personalized medicine, secondary use, artificial intelligence, genome technology, biobank, business ecosystem",
    author = "Jaakko L{\"a}hteenm{\"a}ki and Mari Ervasti and Richard Fagerstr{\"o}m and {van Gils}, Mark and Juha Pajula and Sampsa Ruutu and Anton Sigfrids and Ville Valovirta and Peter Yl{\'e}n",
    year = "2018",
    month = "8",
    day = "29",
    language = "English",
    series = "Research Report",
    publisher = "VTT Technical Research Centre of Finland",
    number = "VTT-R-03318-18",
    address = "Finland",

    }

    Data-driven precision medicine ecosystem - stakeholder needs and opportunities. / Lähteenmäki, Jaakko; Ervasti, Mari; Fagerström, Richard; van Gils, Mark; Pajula, Juha; Ruutu, Sampsa; Sigfrids, Anton; Valovirta, Ville; Ylén, Peter.

    VTT Technical Research Centre of Finland, 2018. 74 p. (Research Report; No. VTT-R-03318-18).

    Research output: Book/ReportPublished reportResearch

    TY - BOOK

    T1 - Data-driven precision medicine ecosystem - stakeholder needs and opportunities

    AU - Lähteenmäki, Jaakko

    AU - Ervasti, Mari

    AU - Fagerström, Richard

    AU - van Gils, Mark

    AU - Pajula, Juha

    AU - Ruutu, Sampsa

    AU - Sigfrids, Anton

    AU - Valovirta, Ville

    AU - Ylén, Peter

    PY - 2018/8/29

    Y1 - 2018/8/29

    N2 - This report summarizes the results of the first phase of VTT's PreMed project. It provides an overview of the Finnish precision medicine landscape and business opportunities opened by secondary use of health related data as enabled by biobanks and other data sources. The observations are based on openly available information and interviews of key stakeholders. The report describes the Finnish infrastructure supporting secondary use and covers the existing entities (e.g. biobanks), entities currently in development (e.g. the Service Operator and Genome Center) and related national activities, most notably the FinnGen project. It is concluded that the Finnish infrastructure is well-developed and internationally competent, but there are worries among the stakeholders concerning the delays in setting up the components under development. Analysis of international developments reveals that a large number of efforts is on-going targeted at collecting genome data, supporting co-operation and improving access to data and processing tools. Although the international market potential is high, most Finnish SME's in the precision medicine domain still have difficulties in generating profitable business. The related reasons and bottlenecks are analysed and new business opportunities are analysed in the report. The potential of Artificial Intelligence is specifically addressed as a technology powered by the increased availability of health data for secondary use. The report provides an analysis of business opportunities in four areas covering new therapy development, health risk assessment and diagnostics, therapy selection and direct-to-consumer genomics. The analysis provides policies and strategies, which should be adopted to remove the main barriers. It is widely understood that successful business in data-driven precision medicine relies on networked stakeholders. In order to understand the mechanisms of the business ecosystem an initial ecosystem model has been constructed in the PreMed project. The model enables simulation of different alternative development paths for the precision medicine ecosystem. The report forms the basis for further work planned to be carried out in the PreMed project, which is scheduled to be completed by April 2020.

    AB - This report summarizes the results of the first phase of VTT's PreMed project. It provides an overview of the Finnish precision medicine landscape and business opportunities opened by secondary use of health related data as enabled by biobanks and other data sources. The observations are based on openly available information and interviews of key stakeholders. The report describes the Finnish infrastructure supporting secondary use and covers the existing entities (e.g. biobanks), entities currently in development (e.g. the Service Operator and Genome Center) and related national activities, most notably the FinnGen project. It is concluded that the Finnish infrastructure is well-developed and internationally competent, but there are worries among the stakeholders concerning the delays in setting up the components under development. Analysis of international developments reveals that a large number of efforts is on-going targeted at collecting genome data, supporting co-operation and improving access to data and processing tools. Although the international market potential is high, most Finnish SME's in the precision medicine domain still have difficulties in generating profitable business. The related reasons and bottlenecks are analysed and new business opportunities are analysed in the report. The potential of Artificial Intelligence is specifically addressed as a technology powered by the increased availability of health data for secondary use. The report provides an analysis of business opportunities in four areas covering new therapy development, health risk assessment and diagnostics, therapy selection and direct-to-consumer genomics. The analysis provides policies and strategies, which should be adopted to remove the main barriers. It is widely understood that successful business in data-driven precision medicine relies on networked stakeholders. In order to understand the mechanisms of the business ecosystem an initial ecosystem model has been constructed in the PreMed project. The model enables simulation of different alternative development paths for the precision medicine ecosystem. The report forms the basis for further work planned to be carried out in the PreMed project, which is scheduled to be completed by April 2020.

    KW - precision medicine

    KW - personalized medicine

    KW - secondary use

    KW - artificial intelligence

    KW - genome technology

    KW - biobank

    KW - business ecosystem

    M3 - Published report

    T3 - Research Report

    BT - Data-driven precision medicine ecosystem - stakeholder needs and opportunities

    PB - VTT Technical Research Centre of Finland

    ER -